FI861559A - A method for producing a protein comprising the proteins encoded by the coding region of the PreS1-PreS2-S protein of the hepatitis B virus surface antigen and the recombinant DNA vectors and contaminants and mammalian cells used in the method - Google Patents

A method for producing a protein comprising the proteins encoded by the coding region of the PreS1-PreS2-S protein of the hepatitis B virus surface antigen and the recombinant DNA vectors and contaminants and mammalian cells used in the method Download PDF

Info

Publication number
FI861559A
FI861559A FI861559A FI861559A FI861559A FI 861559 A FI861559 A FI 861559A FI 861559 A FI861559 A FI 861559A FI 861559 A FI861559 A FI 861559A FI 861559 A FI861559 A FI 861559A
Authority
FI
Finland
Prior art keywords
protein
pres1
pres2
coding region
hepatitis
Prior art date
Application number
FI861559A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI95045B (en
FI95045C (en
FI861559A0 (en
Inventor
John S Salstrom
Mark L Rohrbaugh
Hans A Thoma
Original Assignee
Endotronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endotronics Inc filed Critical Endotronics Inc
Publication of FI861559A0 publication Critical patent/FI861559A0/en
Publication of FI861559A publication Critical patent/FI861559A/en
Priority to FI914267A priority Critical patent/FI95726C/en
Publication of FI95045B publication Critical patent/FI95045B/en
Application granted granted Critical
Publication of FI95045C publication Critical patent/FI95045C/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Bacterial plasmids carrying the PreS1-PreS2-S protein coding region, but lacking sequences encoding the hepatitis B core antigen, which are used for transfection of eukaryotic cell lines for the production of particles containing polypeptides encoded by the PreS1-PreS2-S protein coding region.
FI861559A 1985-04-15 1986-04-14 A method for producing a protein comprising the proteins encoded by the coding region of the PreS1-PreS2-S protein of the hepatitis B virus surface antigen, and the recombinant DNA vectors and contaminants and mammalian cells used in the method FI95045C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI914267A FI95726C (en) 1985-04-15 1991-09-10 Diagnostic methods and kits using recombinant hepatitis B virus surface antigen

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP85104521 1985-04-15
EP85104521 1985-04-15
US85056786A 1986-04-11 1986-04-11
US85056786 1986-04-11

Publications (4)

Publication Number Publication Date
FI861559A0 FI861559A0 (en) 1986-04-14
FI861559A true FI861559A (en) 1986-10-16
FI95045B FI95045B (en) 1995-08-31
FI95045C FI95045C (en) 1995-12-11

Family

ID=26096680

Family Applications (1)

Application Number Title Priority Date Filing Date
FI861559A FI95045C (en) 1985-04-15 1986-04-14 A method for producing a protein comprising the proteins encoded by the coding region of the PreS1-PreS2-S protein of the hepatitis B virus surface antigen, and the recombinant DNA vectors and contaminants and mammalian cells used in the method

Country Status (9)

Country Link
KR (1) KR960004264B1 (en)
AU (1) AU606574B2 (en)
DK (1) DK171386A (en)
FI (1) FI95045C (en)
HU (1) HUT40699A (en)
NO (1) NO861450L (en)
NZ (1) NZ215820A (en)
OA (1) OA08238A (en)
PT (1) PT82392B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619753B2 (en) * 1987-06-22 1992-02-06 Medeva Holdings B.V. Hepatitis b surface antigen vaccine

Also Published As

Publication number Publication date
FI95045B (en) 1995-08-31
NZ215820A (en) 1989-01-06
KR960004264B1 (en) 1996-03-30
AU5611486A (en) 1986-10-23
KR860008284A (en) 1986-11-14
DK171386D0 (en) 1986-04-15
DK171386A (en) 1986-10-16
FI95045C (en) 1995-12-11
HUT40699A (en) 1987-01-28
PT82392A (en) 1986-05-01
FI861559A0 (en) 1986-04-14
AU606574B2 (en) 1991-02-14
PT82392B (en) 1988-03-03
NO861450L (en) 1986-10-16
OA08238A (en) 1987-10-30

Similar Documents

Publication Publication Date Title
AP8600035A0 (en) Hepatitis B surface antigen formed by recombinant DNA Techniques, vaccines, diagnostics, cell lines and methods of forming same.
IL87737A (en) Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB2197324B (en) Process for the production of a polypeptide
IL87255A (en) Dna constructs containing a kluyveromycesalpha- factorleader sequence for directingsecretion of heterologouspolypeptides
KR910004803A (en) The parenchymal cell growth factor of the liver, the gene encoding it, the method of producing the factor, and the transformant producing the factor
DE69839553D1 (en) PROCESS FOR THE PRODUCTION OF PROTEINS
DE3382704T2 (en) Recombinant DNA molecules encoding hepatitis B surface antigen, their production and derived vaccines.
FI861559A (en) A method for producing a protein comprising the proteins encoded by the coding region of the PreS1-PreS2-S protein of the hepatitis B virus surface antigen and the recombinant DNA vectors and contaminants and mammalian cells used in the method
ES2080759T3 (en) PRODUCTION OF FUSED PROTEINS OR POLYPEPTIDES.
ATE136057T1 (en) AUTONOMOUSLY REPLICATING DNA FRAGMENTS FROM MAMMAL CELLS WITH AFFINITY FOR DNA-BINDING PROTEINS
EP0422217A4 (en) Human recombinant placental ribonuclease inhibitor and method of production
GB9009522D0 (en) A gene coding for glucuronide permease
DE69932644D1 (en) Human protein with in vitro antiproliferative activity.
NZ511303A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same with homology to Hep27 protein
ATE268819T1 (en) PRO241 POLYPEPTIDES AND NUCLEIC ACIDS CODING THEREOF
SU1380209A1 (en) RECOMBINANT PLASMID DNA PUR 291-HAV 22 ENCODING SYNTHESIS OF HYBRID POLYPEPTIDE OF HEPATITIS VIRUS A ANTIGENIC DETERMINANTS WITH β-GALACTOSIDASE

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: ENDOTRONICS, INC.